Literature DB >> 4024210

Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin response to warfarin therapy: preliminary evaluation.

J M Svec, R W Coleman, D R Mungall, T M Ludden.   

Abstract

The ability of a pharmacokinetic/pharmacodynamic Bayesian forecasting computer program to predict prothrombin response to warfarin therapy was investigated. The performance of the program was evaluated retrospectively in an inpatient study population of 45 subjects. Predictions of prothrombin response at discharge, based on zero to five serially measured prothrombin ratios, were compared. Precision of prediction was measured by root mean squared error (rmse), bias was measured by average prediction error, and significance (p less than 0.05) was determined by 95% confidence intervals and correlation coefficients. Eleven (3.8%) predictions exceeded established limitations of the pharmacokinetic/pharmacodynamic model and were excluded from data analysis. Correlations between measured and predicted prothrombin ratios for all methods were significant. The five prothrombin ratio feedbacks provided the most accurate predictions (rmse 0.219). These predictions were significantly better than the population parameter (rmse 0.418), one (rmse 0.401), and two (rmse 0.459) prothrombin ratio feedback predictions. The predictions based on population parameters and one prothrombin ratio feedback were significantly biased. When provided with sufficient feedback, the bias was not apparent and the predictive performance improved with each additional prothrombin ratio. The predictive performance of the four and five prothrombin ratio feedbacks is sufficient to provide clinically useful dosage guidelines early in the course of warfarin therapy. The population parameter estimates require further delineation in order to improve the performance of limited prothrombin ratio feedback predictions.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4024210     DOI: 10.1097/00007691-198506000-00006

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  9 in total

1.  Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy.

Authors:  B Vadher; D L Patterson; M Leaning
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

Review 2.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

3.  Initiation of warfarin therapy: comparison of physician dosing with computer-assisted dosing.

Authors:  R H White; R Hong; A P Venook; M M Daschbach; W Murray; D R Mungall; R W Coleman
Journal:  J Gen Intern Med       Date:  1987 May-Jun       Impact factor: 5.128

Review 4.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

Review 5.  Methods for clinical monitoring of cyclosporin in transplant patients.

Authors:  R J Dumont; M H Ensom
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

6.  Development of a bayesian forecasting method for warfarin dose individualization.

Authors:  Daniel F B Wright; Stephen B Duffull
Journal:  Pharm Res       Date:  2011-02-08       Impact factor: 4.200

7.  A Bayesian dose-individualization method for warfarin.

Authors:  Daniel F B Wright; Stephen B Duffull
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship.

Authors:  N H Holford
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

9.  Population pharmacokinetics of racemic warfarin in adult patients.

Authors:  D R Mungall; T M Ludden; J Marshall; D W Hawkins; R L Talbert; M H Crawford
Journal:  J Pharmacokinet Biopharm       Date:  1985-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.